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Abstract 
Treatment options and duration of therapy for patients with metastatic renal cell carcinoma (mRCC) have increased. 
Many patients now spend in excess of 2 years on active therapy. These patients’ needs, and the ability of health services 
to respond to them, are poorly understood. Ten patients living with mRCC for more than 2 years and treated with at 
least one targeted agent were selected at random from three hospitals in the United Kingdom (UK). One interviewer 
who was not involved in their care conducted in-depth interviews. Interview transcripts were analysed using 
Interpretative Phenomenological Analysis (IPA) to identify issues of greatest importance to patients, and to understand 
how well patients felt their needs were being addressed. Perceived delay in initial diagnosis was a major theme. Being 
told the truth about treatment side effects upfront was important, but was often at odds with perceived delivery.  
‘Dealing with side effects’, understanding dose and its effects and not letting ‘negative thoughts get in’ were highlighted 
as important, but were highly personal to patients and areas where patients struggled. Concordance was observed with 
delivery of ‘a clear next step’ for treatment, timely access to drugs and guidance on a drug ‘holiday’. Patient experience of 
mRCC and its treatment requires a tailored approach. This research suggests there are key opportunities for service 
improvement and improved communication throughout the pathway to better meet the needs of patients, including 
non-clinical support to build personal resilience.  
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Introduction 
 
Kidney cancer is the 8th most common cancer in the UK, 
affecting almost 10,000 patients per year, and incidence 
has been increasingly rapidly1.  At diagnosis, approximately 
20-30% of renal cell carcinoma (RCC) patients will have 
metastatic disease.  Of those presenting with localised 
disease at diagnosis, up to 30% will go on to relapse with 
distant disease2.   
 
The prognosis for this group of patients with advanced 
disease has historically been poor.  Cytokine therapies have 
been commonly used in the treatment of metastatic renal 
cell carcinoma (mRCC) but with anti-tumour effect limited 
to relatively few patients. Interferon-α (IFN-α) has an 
approximately 11–15% objective response rate in 
appropriately selected individuals3.  Historical median 
survival has been around 14 months in patients treated 
with IFN-α.   
 
In recent years, there has been a rapid expansion of 
treatment options for these patients.  Two classes of 
agents, anti-angiogenic agents targeting vascular 
endothelial growth factor (VEGF) and other pathways, 
and mammalian target of rapamycin (mTOR) inhibitors, 
have been licensed across various lines of therapy giving 
patients more generally efficacious treatment options.  It is 
now possible to treat patients beyond three lines of 
effective therapy. 
 
This step change in the outcomes that can be expected for 
patients presenting with mRCC has resulted in many more 
patients surviving longer with this disease.  Moreover, 
unlike traditional chemotherapy regimens, these newer 
treatments are typically orally administered and are taken 
on a continuous basis while the patient continues to get 
benefit. Patients are now taking more targeted therapies at 
home in pill or capsule form. Once they have adjusted to 
their new treatment, many return to a good level of 
function, and some may return to work. In practice, little is 
known about the needs of people managing their life with 
advanced disease in this way, and whether these needs are 
being correctly identified and met.   
 
In England, the Department of Health (DoH) has 
previously acknowledged the importance of identifying 
and meeting the needs of patients who are still living with 
their cancer alongside those who have had successful, 
curative treatment. This led to the creation of the National 
Cancer Survivorship Initiative (NCSI), a key part of the 
DoH’s Cancer Reform Strategy when it was published in 
2007. Survivorship has been retained in the more recent 
DoH publication ‘Improving Outcomes: A Strategy for 
Cancer’4 with UK charity Macmillan Cancer Support, also 
known as Macmillan, as a key delivery partner. 
 
Recently, the importance of patient experience has been 
further enshrined in the National Health Service (NHS) 
Outcomes Framework for 2013/145, particularly at the 
end of life (defined as the final three months of life), with 
improving the experience of care for people at the end of 
their lives being stated as a priority for the NHS in 
England.  Additionally, the NHS Outcomes Framework 
requires the NHS to strive to enhance the quality of life 
for patients living with long-term conditions, and to 
enhance quality of life for their caregivers.   
 
But while there is much emphasis on improving patient 
care in this setting, and while some research has been 
undertaken into the needs of patients and their caregivers 
across a range of cancer types6, there has been little focus 
specifically on patients with mRCC7.  Given the specific, 
and very recent, changes to the treatment of mRCC and 
the potential for significantly improved patient outcomes 
that these bring, it is important to fully explore whether 
the needs of this group of patients are currently being 
addressed. 
 
The health and social care services previously organised 
and designed to look after these patients may no longer be 
fit for purpose, and patients may not have access to wider 
support and services outside the clinic environment.  
Increasing numbers of patients will be using services for 
longer, and the nature of the disease and the side effects of 
treatment have changed. 
 
The current study aims to understand the needs of patients 
living longer term with metastatic renal cell carcinoma and 
to explore how well patients perceive their needs are being 
met by current services. 
 
Patients and Methods 
 
Participants 
Ten patients attending renal clinics at The Christie 
Hospital (Manchester), Bart’s and the London NHS Trust 
(London) and The Beatson West of Scotland Cancer 
Centre (Glasgow) were enrolled into the study.  These 
participants were adults with stable mRCC diagnosed 
more than 24 months previously and who had been 
treated with one or more targeted therapies (including but 
not limited to sunitinib, sorafenib, pazopanib, 
bevacizumab, temsirolimus or everolimus).  Initial entry 
criteria had included an upper limit of 36 months of 
treatment, but this criterion was removed during the study 
to facilitate recruitment.  Participants were capable of 
giving informed consent to participate and of undergoing 
face-to-face interviews with investigators, either 
independently or through translators. 
 
Methods 
Interpretative phenomenological analysis (IPA), the key 
methodologies of which have been described elsewhere8, 
was employed in this study. Subjects underwent a single, 
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one-to-one semi-structured interview, lasting typically 
between 60 and 90 minutes. Nine subjects were 
interviewed in their own home by the chief investigator, 
one by telephone.  Consent was obtained to audio-record 
each interview in full so that the detailed line-by-line 
analysis of every conversation could be achieved. 
 
The outline structure for the interviews was derived from 
extensive analysis of the literature carried out between 
December 2010 and January 2011. In particular, grey 
literature such as patient Internet chatrooms and for a 
dedicated to kidney cancer were included in the search. 
These sources were analysed similarly to the patient 
interviews (see below) and likely emerging themes were 
identified.  Using these expected emerging themes, the 
interviewer was able to provide direction for the 
conversation if required.  Moreover, the themes identified 
as likely to emerge from the review of the literature could 
be compared to areas proactively raised by patients during 
the interviews.  Themes predicted to arise from the 
literature review prior to the interviews, and those 
summarised in Table 1.  Open-ended questions were used 
to facilitate discussion, but the interviewees were free to 
tell their story in their own way.   
  
Data Analysis 
 
The Chief Investigator, who moderated the interviews, 
and a second researcher who completed an independent 
analysis carried out data analysis.  IPA moderators are 
trained to suspend presuppositions and judgment whilst 
reading the text transcripts, in order to focus on what is 
actually presented in the transcript data. This involves the 
practice of “bracketing”9 – the suspense of critical 
judgment and a temporary refusal of critical engagement, 
which would bring in the researcher’s own assumptions 
and experience10. However, IPA acknowledges a role for 
interpretation. Therefore, once the initial data analysis is 
done, the moderator conducts a second pass, adding their 
interpretation of the meaning of the data. This is then 
integrated across the two assessments of moderator and 
secondary researcher. Two complementary approaches 
were employed; thematic analysis and case study analysis. 
 
The thematic analysis aimed to identify and code key areas 
of importance arising from the interviews, focusing on 
participants’ experiences of the care they received.  All 
interviews were transcribed in full to facilitate analysis.  
Each transcript was then manually coded, with the 
researchers creating a label for each patient comment, 
primarily regarding their experience and perspective of an 
issue.  Line by line labeling of the transcript ensured all 
data were captured for the analysis.  The researcher, 
providing interpretation of the meaning of the patient’s 
comment, then added a further comment. 
 
From these detailed codes, higher-level themes were 
established, aggregating similar experiences together, 
and phrased in the first person in order to represent a 
participant speaking.  In addition, a further 'tag' was added 
which identified when in the patient’s treatment pathway 
the issue occurred (e.g. at diagnosis).  
 
For example, the following excerpt was labeled Panic & 
Rationalisation and fell into the ‘Diagnosis’ point in the 
patient pathway: 
“They wanted to put me through a scan … could my daughter get my 
wife up there?  I thought 'that was not sounding clever'. They kept 
me in … The doctor came up and said "we can't deal with you in 
this hospital, we have got to send you to [another hospital]". … 
"why can't you deal with it?" He said "because this is not lung 
cancer, this has come from your kidney". I thought 'Oh No!'’’ 
 
The themes emerging from the interviews were then 
compared against the themes which were expected to 
emerge from the pre-work to identify any areas which 
were discussed previously in the literature, or are the focus 
of discussion on online support groups, but which were 
not raised by interviewees in this study (Table 1). 
 
To determine how important each theme was, and how 
well current provision met the expectations of patients for 
this theme, all comments relating to each theme were 
grouped and assessed in the context of all the issues rose.  
 
Where the same theme was raised repeatedly both within 
and across interviews, researchers interpreted this as of 
higher importance than those raised less frequently.  For 
example, if all patients stated a need for early diagnosis, 
this was rated as more important than if only one patient 
made the comment. In addition, researchers sought to 
interpret the intensity of the issue rose. This was 
ascertained from a range of 'clues' including the type of 
language used and degree of emphasis placed.  For 
example, high intensity was ascribed to an excerpt using 
words such as "terrifying" and "extremely worried".  In 
this way, an issue that was of extreme importance to a few 
patients would be considered of similar importance to an 
issue raised by all patients, but without the same intensity.  
 
Finally, using case study analysis, consideration was given 
as to how well each theme was delivered against by the 
current service and other sources. Where participants 
described their symptoms as not being recognised, a low 
level of 'delivery' was interpreted.  For example, "I started 
getting pains round about my kidney area in my back.  I 
went to the doctor a few times, and she kept saying it was 
an infection and different things".   
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A visual illustration of the higher level themes and 
patients’ experience of delivery against these was then 
developed, with themes placed chronologically from  
before diagnosis to present time on the ‘lifeline’ chart (see 
Figure 1).   
 
 
Results 
 
10 patients were enrolled into the study with equal 
numbers of men and women and an average age of 64.  
Basic demographics for the patients, including date of first 
diagnosis and their initial treatment for metastatic disease, 
are presented in Table 2.  
 
Table 1: ‘Pre-fieldwork’ shows the list of themes arising from desktop research and a literature review, 
including patient fora and chatrooms dedicated to kidney cancer.  This informed the discussion guide 
(Table 4) for use in the patient interviews.  ‘Post fieldwork’ shows the themes that were actually raised in 
the patient interviews.  The four final high-level themes were plotted as ‘journey steps’ on the lifeline 
(Figure 2). 
Pre-fieldwork  Post-fieldwork  
Symptoms and RCC diagnosis  
1.   No obvious symptoms 
2.   Confusion and disbelief - where did it come from?  
3.   Diagnosis comes out of the blue and is devastating 
4.   A death sentence - panic sets in 
5.   Playing with statistics 
Symptoms and RCC diagnosis  
1. Out of the blue with no obvious symptoms 
2. Panic and rationalisation  
Getting over the shock and seeking options  
6.   A waiting game 
7.   Limited options 
8.   Getting informed and taking some control 
9.   Craving normality 
10. No silver bullet or miracle cure 
Getting over the shock and seeking options  
3. Getting immediate attention  
4. A plan of action  
5. Getting the right information I can trust  
6. Facing reality and acceptance  
Surviving mRCC  
11. A rollercoaster of emotions - coping with the 
constant ups and downs 
12. Extending life and precious time 
13. Life appreciation and 'bucket' lists 
14. A constant fight - ready for the next hit 
15. A different person 
16. Clutching at glimmers of hope 
17. Shared experiences and deep connections 
18. Enduring the treatment and side effects - not giving 
up  
19. Having a wellness plan  
20. Financial burden 
21. Family impact and support 
Finding ways to cope 
7. Ups and downs & complications 
8. Time matters 
9. A different normality 
10. Coping day to day 
11. A different person  
12. Side effects, effectiveness and quality of life  
13. Work and financial implications 
14. Support around you 
On-going monitoring  
22. Running out of options  
23. Scanxiety - dread of mets  
Keeping stable  
15. Prepared to try anything and everything  
16. Size matters (tumour) 
17. Drug reliance and routine 
18. Constancy of care  
Impending final days 
24. Fighting to the end 
25. What you want, not what others expect 
26. Submission  
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Emerging topics and themes 
As can be seen from Table 1, the themes which arose from 
both the pre-work and the interviews could be grouped 
into areas which formed a patient journey from initial 
symptoms and seeking help, through diagnosis and 
treatment and ultimately to discussions about end of life.  
But while the broad topics were consistent, 5 of these 
emerged in the pre-work, with only 4 emerging from 
interview, and the detailed themes which emerged differed 
between the pre-work and interviews in several areas. 
 
Some of the pre-fieldwork themes were more desperate 
and fatal in tone than those arising in the interviews. The 
expected narratives of ‘a death sentence’, ‘limited options’, 
‘fighting to the end’ and ‘submission’ were either reduced 
in their intensity or absent. Themes were more day-to-day 
in emphasis with patients generally on a more even keel, 
albeit reporting ‘ups’ and ‘downs’.   
 
The first two topics, ‘symptoms and RCC diagnosis’ and 
‘getting over the shock and seeking options’ were very 
broadly consistent between the pre- work and the 
interviews.  However, the next phase was described 
following the pre-work as ‘surviving mRCC’, with some 
emphasis on extending life and fighting cancer.  This was 
altered after the fieldwork to ‘finding ways to cope’ with 
the interviewees talking much more about coping day-to-
day and finding a new normality more than fighting 
cancer. 
 
In the pre-work, the 4th and 5th topics were ‘ongoing 
monitoring’ and ‘impending final days’.  The pre-work 
identified a period where patients were anxious about 
scans, and about running out of treatment options, before 
a final stage where patients discussed end of life, death and 
dying.  During interviews, this 4th stage was much more 
about stability, both of tumour size on imaging as well as 
treatment regime.  Fear of running out of options had 
been a major identified theme in the pre-work; a theme 
which did not emerge during the actual interviews.   
 
Pre-work ahead of the study identified a 5th topic, dealing 
with death and impending final days, as being of 
significant concern to patients with RCC and there is 
much discussion, particularly in online support groups, 
about fear of death in particular.  When analyzing this 
study’s results, it became clear that needs around death 
and dying are reflected in research conducted by 
Macmillan that led to the inclusion of ‘I want to die well’ 
in Macmillan’s 9 outcomes, a series of nine statements that 
the charity developed with cancer patients and which they 
want every patient with cancer to be able to say by 203011 
(see Table 3).  Interestingly, patients did not raise death or 
dying in this study.  The methodology used here did not  
F 
 
igure 1: The patient lifeline.  Issues highlighted as important are grouped chronologically from left to right according to where 
they affect the patient during their treatment.  How important these issues are (blue line) is graphed against how well the 
issues are being met (yellow line).  Larger gaps between the lines suggest areas where the most work needs done to meet 
patient needs. 
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Table 2: Baseline characteristics of the included patients 
Participant  Gender  Age  Lead mRCC Treatment  Date of mRCC diagnosis  
1  Female  74  sunitinib Mar 2009  
2  Female  60  sunitinib, interferon  Jan 2009  
3  Male  60  pazopanib  May 2011  
4  Male  62  sunitinib Jun 2010  
5  Female  55  sunitinib, radiation  Jan 2010  
6  Female  66  pazopanib Sep 2010  
7  Male  74  pazopanib Jan 2011  
8  Male  68  pazopanib Jul 2010  
9  Female  62  sunitinib Feb 2010  
10  Male  66  sunitinib Dec 2010  
 
 
Table 3: Macmillan’s 9 outcomes, a series of 9 statements that the UK charity Macmillan Cancer Support report that 
cancer patients want to be able to say in relation to their diagnosis and care. 
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include proactively raising specific issues which were not 
raised by patients, so it is not clear what drove this lack of 
willingness to raise death in this forum. 
 
Lifelines  
The lifelines chart (Figure 1) takes the topics and emerging 
themes and displays them along with graphic 
representation depicting how important these issues were 
to the interviewed patients (blue line), and how well they 
were delivered to the patient (yellow line). 
 
All of the issues listed are of importance to patients. 
Interestingly, in a large number of areas, the care, 
information or support that the patient received did not 
meet with their needs, as can be seen from Figure 1.  The 
largest gaps between importance and under-delivery were 
observed in the following areas: 
 Early diagnosis in order to have more options 
 Coping with side effects through treatment 
 Staying positive through the ‘down cycle’, or 
psychological or physical low points during 
treatment 
 Understanding dosage and effects for them 
 Being prepared for the possibility of side effects. 
 
However there was significant under-delivery in a range of 
other areas including: connecting their diagnosis with 
symptoms; being told the truth about treatment; an 
explanation of who there is to talk to, including outside the 
clinical team; personal goal setting; reaching for special 
moments; finding positives every day; gaining help with 
imposed restrictions, such as travel insurance; and making 
the best of any time off treatment. 
 
In very few areas did delivery of care match or exceed the 
expectations of the patients.  The value of Macmillan in 
helping access financial benefits and the value of other 
professional support (when accessed) were two such areas, 
as were getting the right drug when needed, being given 
treatment breaks where necessary, being told about 
changing tumour size and a relationship with the whole 
team, not just the consultant. 
 
For the first main topic, diagnosis, of particular concern is 
that under-delivery started even before a diagnosis.  The 
patients in this study highlighted a failure to connect the 
symptoms with which they had been suffering to their 
eventual diagnosis, and were upset that the late diagnosis 
left them with few options for treatment, and no prospect 
for cure.   
The second main topic identified in this study was ‘getting 
over the shock and seeking options’.  At this point, the 
participants of this study required a clear next step, and a 
plan of action delivered with sensitivity.  Overall, these 
requirements were met for the patients in this study, 
 
No patient in the sample cohort proactively raised wanting 
to use the internet to access comprehensive details of their 
condition. However, most wanted a simple, truthful 
explanation of their condition, their prognosis, and a clear 
next step, as well as a recommendation from their 
consultant as to the best course of action. Patients also 
wanted to feel involved, and to have all the facts about 
their cancer provided.  In particular, patients in this study 
wanted to see scans and ‘make it tangible’.  The delivery of 
 
 
Figure 2: The relative proportions of time individuals feel like a ‘patient’ compared with feeling more normal (like a 
‘person’). 
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the above was not provided consistently, but elements of 
each were reported.  
 
Macmillan nurses were highly valued for support at this 
stage, even if their initial appearance at diagnosis was 
feared by loved ones as a sign of more significant disease. 
 
One patient stated “The first I really heard of it was when I read 
the piece of paper and I saw the word ‘tumour’.   I thought ‘I hope 
there is not a Macmillan nurse there’, and this other woman walked 
in and she has got a Macmillan nurse and I thought ‘oh shit’. I was 
in almost blind panic then” 
 
‘Patient’ or ‘Person’? 
‘Finding ways to cope’ was a major topic in this study.  
The themes, which patients identified as important under 
this topic, were a mixture of external (such as being well 
prepared by hospital staff for the side effects of medicines) 
and internal (such as finding something positive in every 
day or not letting negative thoughts in).  The participants 
in this study very consistently identified a balance between 
patient and person as being important for them in finding 
ways to cope.  Patients varied during their treatment as to 
where this balance lay for them, but there was even greater 
variation between patients as to where they spent the 
majority of their time (Figure 2).  The extremes of this 
spread are summarised by two patient quotes.  Patient 1, 
who feels like a ‘patient’ the majority of the time, stated, 
‘Now the side effects and treatment are worse than the cancer itself. 
Not long-term of course, but on a living my life day-to-day level, 
much, much worse. I’m on treatment and oh boy … then it’s just 
about getting through each day of the cycle and to the end of it, to feel 
whole again. 
It makes me feel like two people. One who’s fine, normal, human – 
the old me; the other one who’s really sick and has a terminal disease 
and there’s no going back …’.   
 
In contrast, patient 8 managed to find more of a positive 
balance, claiming to feel more like a ‘person’ than a 
‘patient’ for the majority of the time.  Patient 8 stated, ‘Yes 
I have cancer but I just don’t let it get to me. I’m not the only one 
and I don’t want to waste my life feeling sorry for myself. I’m lucky 
actually – I have my husband, children and grandchildren. They keep 
me going. 
It’s about living day by day but also setting targets. Like when we 
celebrated our 45th wedding anniversary.  
They told me the outlook was not good – maybe a year. Well that 
was 3 years ago so I’ve beaten that so what’s stopping me now? 
Yes sometimes the side effects can be inconvenient but nothing worse 
than other illnesses. There are some things I can’t always do or need 
help with but then I’m not getting any younger anyway’.   
 
Patients described the importance of setting personal 
goals, finding something positive to focus on, starting the 
day positively and avoiding negative thoughts.  But 
patients were not always able to achieve this.  Patients in 
this study were conscious that treatment optimization, and 
especially optimization of drug dosage, are key to 
achieving tumour control but also impact side effects. By 
balancing control of disease effectively against presence of 
side effects, patients were best able to define themselves as 
a ‘person’, rather than a ‘patient’ for more of the time, and 
this definition of self as ‘person’ was a key to remaining 
positive.   
 
Those patients that had developed a trusting relationship 
with their clinic nurse in particular felt most engaged in the 
achievement of such balance.  In particular, some nurses 
would suggest a ‘drug break’ if they felt that the patient 
would benefit from a relief or freedom from side effects 
for a period of time. Some patients were wary of coming 
off a treatment that was limiting tumour growth, but 
recognised that their endurance of side effects had its 
limits. Set against this balance, patients felt the nurse best 
identified the consideration of a drug break. 
 
Few patients in this study turned to professional care 
support services on a regular basis. Instead, most turned to 
their spouse and occasionally children to provide care, not 
just for functional help but moral support, and simply to 
provide company. Some mentioned that having access to 
friends (non-family) to be able to discuss non-clinical 
issues (sport, hobbies, current affairs) provided a welcome 
distraction from introspection towards their condition.  
Few individuals mentioned being able to obtain support 
from the wider RCC community, and indeed some actively 
did not want to reach out to such a community. 
 
Where professional external organisations did add 
significant value was in support for managing finances, 
such as getting access to entitled benefits.  In particular, 
Macmillan was praised for helping patients access the 
benefits they were entitled to.  This was important to 
patients, who described issues of work, and the financial 
pressures of not being able to work, as being of particular 
concern to them and their families.  The role of an 
employer was often key.  Some were described as 
exemplary in offering flexibility and support, whilst others 
added to the stress, with patients needing personal legal 
support to settle their employment situation. Advice and 
support for dealing with employers was very difficult to 
come by, and would be welcomed by patients. 
 
The balance of factors exerting their effects on patients 
drove this variation between patients, and the extent to 
which the patient or the person predominates.  These 
were: 
 Patient disposition (optimist or pessimist, 
resilience) 
 External factors, such as family support, financial 
concerns, existence of dependents, etc. 
 The amount of focus on the malignancy 
 Treatment cycle and especially side effects 
Patient needs in advanced Renal Cell Carcinoma, Harris et al. 
Patient Experience Journal, Volume 2, Issue 2 - Fall 2015  150   
 External events, such as Computed Tomography 
(CT) scan results. 
 
Of these, the impact of toxicity was, in this study, 
particularly high, but also very variable.  This was true 
whichever of the two medicines were used, but we have 
focused on the 6 patients who received sunitinib to 
demonstrate that variability.  
Of the patients on sunitinib, patient 10 had relatively little 
toxicity, and showed little fluctuation in mood over the 6 
week cycles.  Patient 9 had more toxicity, and cycled 
between feeling like a ‘patient’ during the 4 weeks on 
treatment, and feeling more like a ‘person’ during the two 
weeks off.  Finally, patient 1 had toxicity which they 
perceived very negatively, such that the negative impact 
extended even into the off treatment period, resulting in 
ongoing anxiety about restarting treatment.  
 
The final topic of concern to patients was ‘keeping stable’.  
This applied both to mood and to the tumour size and 
clinical response.  Patients valued drug holidays where 
possible to help offset side effects, as well as close 
relationships with the whole of the multi-disciplinary 
clinical team to help them feel they were getting access to 
the best advice in a timely manner.  Again, a theme that 
emerged in this topic was that of being told honestly about 
how the tumour was doing, and even being shown the 
scans if possible. Tumour size and stability was perceived 
by patients as both a tangible measurement of stability as 
well as easy to present and understand in lay terms. In this 
study, patients felt very included in their management and 
were extremely appreciative of this involvement. 
 
Discussion 
 
The treatment environment for mRCC is changing rapidly, 
but the impact of these changes on patients’ needs and 
expectations, and how well these are met in practice, has 
been poorly studied. 
 
The current study was designed to use in-depth interviews 
with patients, assessed using IPA, to understand the needs 
of patients living long-term with mRCC, and to explore 
their perceptions of how well these needs are being met.  
In addition, the authors sought to explore attitudes to any 
external support services and networks, and how and 
where such services could be improved.  
 
Poor RCC outcomes in the UK is a particular concern, 
with only two countries in Europe (Denmark and 
Bulgaria) having a lower 5 year survival12.  Among 
proposed explanations is late diagnosis in primary care, 
and this study certainly appears to add some weight to that 
theory.  With the incidence of kidney cancer rising so 
quickly, it is imperative more is done to educate primary 
care physicians and members of the public on the need to 
seek expert advice for persistent suggestive symptoms. In 
analyzing the study results, some progress has been made 
with the commissioning of national campaigns to increase 
public awareness and encourage presentation in primary 
care13. 
 
The diagnosis of RCC is one that comes with quite 
significant shock to patients.  A strong and effective multi-
disciplinary team, including excellent nursing support, is 
crucial to delivering a ‘clear next step’ and a plan of action 
clearly, simply and sensitively, as this had a direct impact 
upon the patients’ ability to develop coping mechanisms. 
Such a team could also equip patients to prepare earlier, 
including developing an understanding of side effects, and 
discussing options for dealing with them.   
 
As the role of the Macmillan nurse is reported to be very 
important, perhaps more could be done to introduce the 
Macmillan nurse in such a way as to mitigate some of the 
fears that patients associate with this job title.  This fear 
may also lie behind the decision of some patients not to 
utilise the nurses’ services from the start but patients 
valued being aware of them. If and when the need to use 
them came, speed of delivery was essential (and was 
reported to be excellent). 
A significant focus of patients in this research was 
characterised by ‘finding ways to cope’.  It was under this 
topic in particular that the major themes identified as 
important to patients were least well delivered against.   
At the time of the pre-work, there were no routinely 
available treatment options for patients whose disease had 
progressed on first line sunitinib or pazopanib in the UK.  
In the time between the pre-work being conducted and the 
study opening to recruitment, further treatment options 
became available to patients.  It would be worth exploring 
further what psychological impact limited access to 
treatment has on patients in the current climate of 
budgetary restrictions and restricted medicines access. 
 
Regular treatment breaks associated with sunitinib 
appeared to help participants in this study establish a 
better balance between ‘patient’ and ‘person’. This 
observation could lend support to the exploration of 
regimens, which include planned treatment breaks such as 
permitting ‘drug holidays’ (where patients with on-going 
clinical benefit from a drug discontinue the drug only to 
restart the same treatment when there is evidence of 
disease progression).  One such study is underway in the 
UK14. 
 
It is interesting to note that whether or not they were 
delivered against, eight out of nine Macmillan patient 
outcomes statements, which have been developed with 
patients who have a form of cancer, would certainly 
appear to be applicable to the patients in our study.  There 
was a lack of expressed desire to be part of a wider cancer 
community and the statement ‘I feel part of a community 
and I’m inspired to give something back’ was not  
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Table 4 – Discussion Guide 
 
PART 1: INTRODUCTION 
Introductory Statement: 
Our discussion today is really all about your personal experience of living with …… 
One of the topics we’re likely to cover is your experience of medicines, including any possible side-effects you may have 
experienced. Should this happen, we are required to report these details to the sponsor of our study, who is a manufacturer of 
medicines. This is so that they can learn more about the safety of their medicines, esp. as some side effects may not be 
discovered until many people have used a medicine over a period of time. Everything else we discuss today will be treated in 
confidence and made anonymous – it is solely if you mention a side effect you, or someone you know, has experienced. Are 
you happy to proceed with the interview on this basis?’ [If yes] – So, we have a little bit of paperwork to complete before we 
start, with a few statements to read, and you’ll find one of them talks about “adverse events” – this is what healthcare 
professionals tend to call side-effects. 
 
Establish rapport: 
- how are you feeling today? 
- How has your day been so far? 
PART 2: YOUR EXPERIENCE 
1. Can you tell me about how this all began?  
PROMPTS:  early signs or symptoms? Explanations to yourself? Your awareness? 
Where did you look for information / advice / help? 
2. And from that point of awareness, how did you get to a point of getting a diagnosis? 
PROMPTS:  length of time, stages described, accuracy   
3. What was your experience of doctors and the medical profession at the diagnosis stage? 
PROMPTS:  What was good, what was bad?  What would have helped? 
4. What can you tell me about your thoughts and emotions after diagnosis? 
PROMPTS:  sharing the news with family and friends, other relationships, work and other roles 
5. At that stage what were your priorities?   
PROMPTS:  longevity, quality of life, alleviating symptoms, gaining control 
6. What were your thoughts and feelings about treatment or treatment options? 
PROMPTS:  role of medical practitioners, treatment centres, managing symptoms, dependency on treatments, what is 
good, what is bad? 
7. What are your thoughts about keeping going with the treatments? 
PROMPTS:  motivation?  Influences? What would help improve treatment?  
8. Can you describe day-to-day living for me a little? The ups-and-downs? 
PROMPTS: what makes for a good/bad day? Missing from the past? Expectations? Emotions?\ 
9. Aside from the physical changes, to what degree do you think living with your condition has changed you as a person? 
PROMPTS:  your attitude / character? Outlook? Relationships? Gained/lost? Have changes been slow, steady, sudden? 
10. What helps you cope with everyday life? 
PROMPTS:  Adaptions, coping mechanisms? Identified by? (trial/error, advice) 
11. And can I ask what areas of life are more difficult to cope with? What are the things that you would most want to 
improve / recover more normality of? 
PROMPTS: Activities, family/relationships, ambition/achievement 
 
LOOKING FORWARD 
11. What are your priorities now?  And for the future? 
PROMPTS:  Longevity, well-being, wellness plan, financial planning/mgt, alleviation of symptoms etc.  
 
THANK AND CLOSE 
 
Table 4: The above discussion guide with thematic prompts was used to aid structure within the conversation, without 
restricting or leading the interview flow unnecessarily. The discussion guide was not used as a set of questions to be 
systematically asked. Instead, it was used flexibly, supporting the participant to tell their own individual story, and the 
moderator to be an ‘active listener’. Prompts were used where the interview lacked its own spontaneous course and to help 
establish rapport and rhythm to the interview. IPA methodology encourages the participant to set the parameters of the 
discussion and to follow the path of their own experience. This is key, as a predetermined set of criteria may not all have been 
relevant for each of the 10 participants. 
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articulated by our patient group as important, and perhaps 
should be reconsidered by Macmillan. 
 
Caution should be exercised before extrapolating our 
findings to the broader cancer population, or indeed the 
broader mRCC population. The patients studied here were 
from a sizeable group of outliers in that, for the most part, 
they had significantly exceeded ‘average’ life expectancy 
from this disease and had been on treatment for 
significantly longer than the average duration. This may 
well have impacted on various observations – for example, 
the failure of these patients to pro-actively raise the issues 
surrounding terminal care may reflect the fact that these 
patients were all some distance from the time of initially 
being told of their terminal prognosis, and none of them 
were imminently entering the terminal stage of their 
illness. It is quite possible that a group of patients who 
were experiencing an altogether shorter journey from 
diagnosis to death would have put much greater emphasis 
on this aspect. Conversely, the effects of chronic treatment 
side effects are likely to be of higher impact in the 
population studied here. 
 
Given the variation that exists, the care and treatment of 
patients with mRCC needs to be individualised not only in 
relation to drug treatment but the targeting and provision 
of information, and of clinical and non-clinical support 
services.  Further work to understand how best to assess 
the changing needs of patients with mRCC over time 
could prove valuable. 
 
Summary 
The current study provides rich insight through individual 
patient narratives into the many challenges which the 
welcome improvement in renal cancer outcomes have 
provided in recent years. 
 
The lifelines chart demonstrates which issues are 
important to patients, and provides good insight into 
where their important concerns are, or are not, being met. 
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